Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.25 USD
+0.01 (3.59%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.25 0.00 (-0.40%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for Viracta Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -51.06 | -49.20 | -114.76 | -21.61 | -23.33 |
Depreciation/Amortization & Depletion | -1.56 | -0.42 | 0.18 | -0.01 | 0.05 |
Net Change from Assets/Liabilities | 5.08 | 0.61 | 1.68 | -0.32 | -0.65 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.65 | 13.55 | 94.05 | 0.49 | 1.75 |
Net Cash From Operating Activities | -39.89 | -35.46 | -18.85 | -21.44 | -22.19 |
Property & Equipment | -0.14 | -0.05 | -0.25 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 17.14 | 0.00 | 0.00 |
Investments | 15.14 | -53.82 | 0.00 | 16.41 | -16.29 |
Other Investing Activities | 0.00 | 0.00 | -4.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 15.00 | -53.87 | 12.89 | 16.41 | -16.29 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.44 | 2.56 | 62.66 | 12.68 | 45.08 |
Issuance (Repayment) of Debt | 0.00 | 19.99 | -0.23 | 0.00 | 5.45 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | -5.50 | -7.50 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.44 | 22.54 | 62.43 | 7.18 | 43.04 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -24.46 | -66.78 | 56.47 | 2.15 | 4.57 |
Cash at Beginning of Period | 36.77 | 103.55 | 47.09 | 18.26 | 13.70 |
Cash at End of Period | 12.32 | 36.77 | 103.55 | 20.41 | 18.26 |
Diluted Net EPS | -1.32 | -1.30 | -3.60 | -5.36 | -9.45 |
Fiscal Year End for Viracta Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -18.97 | -9.14 | -51.06 | -37.29 | -24.69 |
Depreciation/Amortization & Depletion | -0.35 | -0.23 | -1.56 | -1.21 | -0.82 |
Net Change from Assets/Liabilities | -1.56 | -0.32 | 5.08 | 2.77 | 2.09 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.21 | 1.84 | 7.65 | 5.87 | 4.09 |
Net Cash From Operating Activities | -17.68 | -7.85 | -39.89 | -29.87 | -19.33 |
Property & Equipment | 0.00 | 0.00 | -0.14 | -0.14 | -0.19 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 25.90 | 14.19 | 15.14 | 5.87 | -3.18 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 25.90 | 14.19 | 15.00 | 5.73 | -3.37 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.12 | 0.08 | 0.44 | 0.22 | 0.22 |
Issuance (Repayment) of Debt | -6.68 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | -6.68 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -6.56 | -6.60 | 0.44 | 0.22 | 0.22 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.66 | -0.26 | -24.46 | -23.92 | -22.48 |
Cash at Beginning of Period | 12.32 | 12.32 | 36.77 | 36.77 | 36.77 |
Cash at End of Period | 13.98 | 12.06 | 12.32 | 12.86 | 14.29 |
Diluted Net EPS | -0.25 | -0.23 | -0.35 | -0.33 | -0.32 |